المؤلفون: Ballas MS, Chachoua A

المصدر: OncoTargets and Therapy, Vol 2011, Iss default, Pp 43-58 (2011)

مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: http://www.dovepress.com/rationale-for-targeting-vegf-fgf-and-pdgf-for-the-treatment-of-nsclc-a7552; https://doaj.org/toc/1178-6930

URL الوصول: https://doaj.org/article/e4ab7f006d6343f48e7c5d379de2c6fb

المؤلفون: Callander, NS, Ribrag, V, Richardson, PG, Nooka, AK, Song, K, Uttervall, K, Minnema, MC, Weisel, K, Quach, H, Min, CK, Ballas, MS, Li, XF, Ratia, N, Kaisermann, M, Holkova, B, Tudel, S

المصدر: BLOOD. 138

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:150515723

المؤلفون: Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR, Gitlitz, Barbara J, Tsao-Wei, Denice D, Groshen, Susan, Davies, Angela, Koczywas, Marianna, Belani, Chandra P

المصدر: Journal of Thoracic Oncology; 2012 Mar, Vol. 7 Issue 3, p574-578, 5p

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Komiya T; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA takefumi.komiya@parkview.com.; Parkview Cancer Institute, Wayne, Indiana, USA., Blumenthal GM; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., DeChowdhury R; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Fioravanti S; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Ballas MS; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.; GlaxoSmithKline, Philadelphia, Pennsylvania, USA., Morris J; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.; University of Cincinnati, Cincinnati, Ohio, USA., Hornyak TJ; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.; VA Medical Center, Baltimore, Maryland, USA., Wank S; National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA., Hewitt SM; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Morrow B; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Memmott RM; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Rajan A; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Dennis PA; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.; AstraZeneca, Gaithersburg, Maryland, USA.

المصدر: The oncologist [Oncologist] 2019 Dec; Vol. 24 (12), pp. 1510-e1265. Date of Electronic Publication: 2019 Jul 26.

نوع المنشور: Journal Article; Research Support, N.I.H., Intramural

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: Anti-Bacterial Agents/*therapeutic use , Hamartoma Syndrome, Multiple/*drug therapy , PTEN Phosphohydrolase/*genetics , Sirolimus/*therapeutic use, Adult ; Aged ; Anti-Bacterial Agents/pharmacology ; Female ; Germ-Line Mutation ; Humans ; Male ; Middle Aged ; Pilot Projects ; Sirolimus/pharmacology ; Young Adult

المؤلفون: Bauer TM; Sarah Cannon Research Institute, Nashville, Tennessee; Tennessee Oncology, PLLC, Nashville, Tennessee., Besse B; Gustave-Roussy Cancer Campus, Cancer Medicine Department, Villejuif, France; Paris-Sud University, Orday, France., Martinez-Marti A; Vall d' Hebrón Institute of Oncology and University Hospital, Barcelona, Spain., Trigo JM; University Hospital Virgen de la Victoria, Málaga, Spain., Moreno V; START Madrid-FJD, Jiménez Díaz Foundation Hospital, Madrid, Spain., Garrido P; Ramón y Cajal University Hospital, IRYCIS, Alcalá University, Madrid, Spain., Ferron-Brady G; GlaxoSmithKline, Collegeville, Pennsylvania., Wu Y; GlaxoSmithKline, Collegeville, Pennsylvania., Park J; GlaxoSmithKline, Collegeville, Pennsylvania., Collingwood T; GlaxoSmithKline, Collegeville, Pennsylvania., Kruger RG; GlaxoSmithKline, Collegeville, Pennsylvania., Mohammad HP; GlaxoSmithKline, Collegeville, Pennsylvania., Ballas MS; GlaxoSmithKline, Collegeville, Pennsylvania., Dhar A; GlaxoSmithKline, Collegeville, Pennsylvania., Govindan R; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. Electronic address: rgovindan@wustl.edu.

المصدر: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Oct; Vol. 14 (10), pp. 1828-1838. Date of Electronic Publication: 2019 Jun 28.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Salvage Therapy*, Benzoates/*therapeutic use , Cyclopropanes/*therapeutic use , Drug Resistance, Neoplasm/*drug effects , Lung Neoplasms/*drug therapy , Neoplasm Recurrence, Local/*drug therapy , Small Cell Lung Carcinoma/*drug therapy, Adolescent ; Adult ; Aged ; Benzoates/pharmacokinetics ; Cyclopropanes/pharmacokinetics ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/pathology ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Small Cell Lung Carcinoma/pathology ; Survival Rate ; Tissue Distribution ; Young Adult

المؤلفون: Komiya T; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Memmott RM; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Blumenthal GM; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Bernstein W; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Ballas MS; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., De Chowdhury R; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Chun G; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Peer CJ; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Figg WD; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Liewehr DJ; Biostatistics and Data Management Section, National Cancer Institute, Rockville, MD, USA., Steinberg SM; Biostatistics and Data Management Section, National Cancer Institute, Rockville, MD, USA., Giaccone G; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Szabo E; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.; Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA., Kawabata S; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Tsurutani J; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Rajan A; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Dennis PA; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

المصدر: Translational lung cancer research [Transl Lung Cancer Res] 2019 Jun; Vol. 8 (3), pp. 247-257.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Pioneer Bioscience Publishing Company Country of Publication: China NLM ID: 101646875 Publication Model: Print Cited Medium: Print ISSN: 2218-6751 (Print) Linking ISSN: 22186751 NLM ISO Abbreviation: Transl Lung Cancer Res Subsets: PubMed not MEDLINE

المؤلفون: Camidge DR; University of Colorado Anschutz Medical Campus, Aurora, CO; †New York University School of Medicine, New York, NY; ‡University of California San Francisco, San Francisco, CA; §Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY; ‖Tower Hematology Oncology Medical Group, Beverly Hills, CA; ¶King's College London, Guy's Hospital, London, United Kingdom; #Swedish Cancer Institute, Seattle, WA; **ImClone Systems, a Wholly-owned Subsidiary of Eli Lilly and Company, Bridgewater, NJ; and ††Cedar Sinai Medical Center, Los Angeles, CA., Berge EM, Doebele RC, Ballas MS, Jahan T, Haigentz M Jr, Hoffman D, Spicer J, West H, Lee P, Yang L, Joshi A, Gao L, Yurasov S, Mita A

المصدر: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2014 Oct; Vol. 9 (10), pp. 1532-9.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*drug therapy , Lung Neoplasms/*drug therapy, Adult ; Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/pharmacokinetics ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Carboplatin/administration & dosage ; Carboplatin/pharmacokinetics ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Disease-Free Survival ; Female ; Humans ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Paclitaxel/administration & dosage ; Paclitaxel/pharmacokinetics ; Ramucirumab

المؤلفون: Blumenthal GM; Medical Oncology Branch, National Cancer Institute, Bethesda, MD., Gills JJ; Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Ballas MS; Medical Oncology Branch, National Cancer Institute, Bethesda, MD., Bernstein WB; Medical Oncology Branch, National Cancer Institute, Bethesda, MD., Komiya T; Medical Oncology Branch, National Cancer Institute, Bethesda, MD., Dechowdhury R; Medical Oncology Branch, National Cancer Institute, Bethesda, MD., Morrow B; Medical Oncology Branch, National Cancer Institute, Bethesda, MD., Root H; Medical Oncology Branch, National Cancer Institute, Bethesda, MD., Chun G; Medical Oncology Branch, National Cancer Institute, Bethesda, MD., Helsabeck C; Medical Oncology Branch, National Cancer Institute, Bethesda, MD., Steinberg SM; Biostatistics and Data Management Section, National Cancer Institute, Bethesda, MD., LoPiccolo J; Medical Oncology Branch, National Cancer Institute, Bethesda, MD., Kawabata S; Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Gardner ER; Medical Oncology Branch, National Cancer Institute, Bethesda, MD., Figg WD; Medical Oncology Branch, National Cancer Institute, Bethesda, MD., Dennis PA; Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

المصدر: Oncotarget [Oncotarget] 2014 Sep 30; Vol. 5 (18), pp. 8161-72.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Intramural

بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , HIV Protease Inhibitors/*therapeutic use , Nelfinavir/*therapeutic use , Neoplasms/*drug therapy, Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Drug Administration Schedule ; Female ; HIV Protease Inhibitors/administration & dosage ; HIV Protease Inhibitors/adverse effects ; HIV Protease Inhibitors/pharmacokinetics ; Humans ; Male ; Maryland ; Maximum Tolerated Dose ; Middle Aged ; Nelfinavir/administration & dosage ; Nelfinavir/adverse effects ; Nelfinavir/pharmacokinetics ; Neoplasms/pathology ; Time Factors ; Tomography, X-Ray Computed ; Treatment Outcome ; Young Adult